Fibrosis

Fibrosis, or pathological scarring, is a debilitating process that involves excessive deposition of connective tissue in the liver, lungs, kidneys, and a number of other tissues. Fibrotic disorders afflict over 40 million people and are estimated to be responsible for up to 50% of all deaths in the United States.

TGFβ1 in the connective tissue microenvironment has been firmly established as a central mediator of this disease process.  Selectively inhibiting the activity of TGFβ1 at the source of disease in the tissue microenvironment by blocking supracellular activation, our emerging medicines are designed to treat fibrosis while avoiding known toxicities caused by less selective inhibition of signaling mediated by a broader set of TGFβ superfamily members.

In addition, the TGFβ superfamily member, BMP7, is known to have protective effects in certain types of fibrosis. Scholar Rock’s approach to locally activating this growth factor in the connective tissue milieu is designed to protect affected organs from further damage.

CONTACT  |  SITEMAP  | 
 |  SITE DESIGN
“Scholar Rock” is a registered trademark of Scholar Rock, Inc.  |  © 2017 Scholar Rock All Rights Reserved.
Back to Top
 

The site you are about to visit is maintained by another organization, which is solely responsible for its content. As we cannot control the content or privacy practices of any third-party websites, we encourage you to read the privacy policy of every website you visit.

Continue   Cancel